RIVANNA

The most consequential advances in ultrasound emerge where imaging physics, system design, machine learning, and clinical application intersect. RIVANNA develops at that intersection, integrating all four into systems that automate complex anatomical analysis and support the next clinical action at the point of care. The Gordon Research Conferences (GRC) meeting on In Vivo Ultrasound Imaging puts investigators working across acoustic hardware, image formation, machine learning, and clinical translation into the same conversation for five days. RIVANNA Director of R&D Paul Sheeran, PhD, will be there August 16 to 21 in Waterville Valley, New Hampshire. On Monday morning, the program devotes three and a half hours to Applications of Machine Learning in Ultrasound, an area central to RIVANNA's work integrating ultrasound system design, acquisition control, and machine learning at the point of care. Beyond the formal program, Paul is interested in connecting with two groups. 👉 Academic investigators interested in using RIVANNA systems in research. We support collaborations that can extend the clinical and technical applications of our technology and are open to developing new ones. 👉 Scientists and engineers considering where to apply their expertise next. As RIVANNA enters the next phase of R&D, we are building the team that will help advance it. 📍 Attending GRC? Paul will be at Board 27 during the Wednesday and Thursday poster sessions. If you are not attending, but either of those conversations applies to you, message him directly. #Ultrasound #MachineLearning #MedicalImaging #MedTech

Women who had spinal fusion surgery as adolescents are still being told they cannot have an epidural. A case series published in the International Journal of Obstetric Anesthesia documents four successful neuraxial procedures in three of these patients at Westchester Medical Center and New York Medical College, performed by four different anesthesiologists. One patient told the authors she had searched the medical literature before her delivery, found nothing on successful spinal or epidural anesthesia after scoliosis surgery, and ended up relying on Reddit and medical blogs. Another said she had been scared and did not know what to expect. 👉 The authors are direct about the conclusion: neuraxial anesthesia should not be withheld from these patients because they have spine instrumentation. They identify antenatal anesthesia consultation, knowledge of the lowest instrumented vertebra, and familiarity with neuraxial ultrasound as the factors that make these procedures succeed. The paper names Accuro among the ultrasound options for difficult neuraxial anatomy. In one case, the anesthesiologist attempted the L4-L5 interspace using anatomical landmarks without success, then placed the epidural catheter at that same interspace under ultrasound guidance. That is the clinical territory we work in. The patients whose anatomy falls outside what palpation can resolve are the ones who absorb the cost of that limitation, and the literature is beginning to say so plainly. With thanks to the authors: Egor Smirnov, S. Yaghoubian, E. Leer, A. Genis, D. Delbello, and Sangeeta Kumaraswami. Abstract: https://lnkd.in/gkWieBkD

This week in Irving, Texas, RIVANNA is joining the American College of Emergency Physicians and the Emergency Medicine Foundation for the ACEP|EMF Partner Collaborative Summit to discuss a practical challenge in emergency care: bringing musculoskeletal imaging closer to the point of triage when radiography capacity is constrained. RIVANNA Chairman, CEO & Co-founder Will Mauldin, PhD, and Delphine Le Roux, PhD, PMP, Sr. Director, Market Access & Strategic Partnerships, will meet with emergency physicians, ACEP and EMF leaders, and industry partners to discuss the role of clinical decision support tools in emergency care and the reimbursement pathways needed to support their adoption. The recent FDA 510(k) clearance of Accuro XV for musculoskeletal imaging makes this an especially timely conversation: https://lnkd.in/g4dVJjEw Attending the Summit? We would welcome the opportunity to connect. #EmergencyMedicine #MusculoskeletalImaging #PointOfCareUltrasound

How does AI earn clinical trust during procedures? On Outcomes Rocket Media, a healthcare leadership podcast recorded at DeviceTalks Boston, RIVANNA Co-founder and CEO Will Mauldin, PhD, notes that AI adds the most value when it confirms clinical judgment rather than replacing it. Spinal anesthesia is often guided by manual landmark palpation without a direct view of the epidural space. Accuro 3S addresses that gap by pairing ultrasound with integrated image-processing software that overlays automated interpretation onto the ultrasound view. Anesthesia providers first read a familiar image, then use AI interpretation for confirmation. Mauldin describes a clear adoption arc where providers initially cross-check the AI and increasingly rely on it as consistent outcomes build confidence. The same decision-support architecture applies to musculoskeletal care, where the clinical challenge takes on a different shape. As many as 20 million patients present to emergency departments and urgent care centers each year with suspected wrist and ankle fractures. In 70 to 80 percent of cases, no fracture is found, yet most patients still undergo radiographic evaluation, sustaining demand on radiology capacity. Accuro XV received FDA clearance in 2026 as a diagnostic ultrasound system. A deep learning model trained across leading academic medical centers is advancing toward clearance to support fracture triage at the point of care. Listen to the full conversation: https://lnkd.in/g69bTDup #MedTech #ClinicalDecisionSupport #PointOfCareUltrasound

How does AI earn clinical trust during procedures? On Outcomes Rocket Media, a healthcare leadership podcast recorded at DeviceTalks Boston, RIVANNA Co-founder and CEO Will Mauldin, PhD, notes that AI adds the most value when it confirms clinical judgment rather than replacing it. Spinal anesthesia is often guided by manual landmark palpation without a direct view of the epidural space. Accuro 3S addresses that gap by pairing ultrasound with integrated image-processing software that overlays automated interpretation onto the ultrasound view. Anesthesia providers first read a familiar image, then use AI interpretation for confirmation. Mauldin describes a clear adoption arc where providers initially cross-check the AI and increasingly rely on it as consistent outcomes build confidence. The same decision-support architecture applies to musculoskeletal care, where the clinical challenge takes on a different shape. As many as 20 million patients present to emergency departments and urgent care centers each year with suspected wrist and ankle fractures. In 70 to 80 percent of cases, no fracture is found, yet most patients still undergo radiographic evaluation, sustaining demand on radiology capacity. Accuro XV received FDA clearance in 2026 as a diagnostic ultrasound system. A deep learning model trained across leading academic medical centers is advancing toward clearance to support fracture triage at the point of care. Listen to the full conversation: https://lnkd.in/g69bTDup #MedTech #ClinicalDecisionSupport #PointOfCareUltrasound

This Thursday at 2 pm, RIVANNA co-founder and CEO Will Mauldin will present Accuro 3S at the MedTech Innovator OpenRounds Showcase, part of Wilson Sonsini's Medical Device & Digital Health Conference in San Francisco. Accuro 3S is the first FDA-cleared system to offer real-time guidance and AI-driven landmark detection for neuraxial anesthesia, a procedure that remains the last major in anesthesiology to be typically performed without real-time image guidance. In the past year, Accuro 3S, SpineNav-AI, and the single-use Needle Guide Kit received FDA clearance. SafeTrack needle-tip tracking is currently under review. Additional developments include a limited market release to select sites planned for Q4 and a dedicated ICD-10-PCS procedure code recommended by CMS, proposed to take effect in October 2026. If you are interested in AI that advances established procedures, connect with Will at the showcase or in the Partnering Hall. #MDC2026 #MedTechAI

RIVANNA returns to the MedTech Innovator Summit in San Francisco this week, one year after joining the 2025 cohort, with a focus on Accuro 3S. This focus is timely: neuraxial anesthesia is the last major anesthesiology procedure typically performed without real-time image guidance. Placements rely on palpation, and while most succeed, a misplaced needle can cause serious complications. The barrier is physical: a conventional ultrasound probe sits where the needle must pass, blocking a midline approach. Accuro 3S addresses this challenge. Its center-channel probe allows a midline needle approach, while SpineNav-AI identifies the epidural space and depth, delivering the real-time guidance the procedure currently lacks. In the past year, Accuro 3S, SpineNav-AI, and the single-use Needle Guide Kit received FDA clearance. SafeTrack needle-tip tracking is under FDA review. Accuro 3S exemplifies RIVANNA's approach to decision-grade ultrasound through integrated imaging hardware and scalable AI interpretation. This foundation supports a second FDA-cleared product line in another market, and each new application expands the platform’s reach without altering the core. If you are interested in supporting AI-enabled systems that advance established procedures, reach out to our co-founder and CEO, Will Mauldin, to schedule a meeting or conversation at the Summit. #InnovatorSummit #MedTech #PointOfCareUltrasound

RIVANNA has been named CBIC Innovator of the Year at the 2026 Charlottesville Business Innovation Council (CBIC) Awards Gala. Thank you, CBIC. And congratulations to fellow finalists Springbok Analytics and VerifyYou. What started in 2010 in a home attic (with toaster-oven circuit boards, trailer-hitch transducers, and a deer-spine phantom) has grown into a medical technology company that translates validation earned from the most rigorous technical buyers in healthcare into commercial deployment. Competitive federal awards become FDA-cleared products, each paired with a commercial program that meets clinicians where they work. Everything we've built so far is the foundation for what comes next. This award belongs to the entire RIVANNA team, transforming point-of-care decision-making in neuraxial anesthesia and emergency fracture care. And it reflects a #Charlottesville innovation ecosystem that keeps proving what a focused community can build.